These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12792364)

  • 21. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.
    Purnell JQ; Zambon A; Knopp RH; Pizzuti DJ; Achari R; Leonard JM; Locke C; Brunzell JD
    AIDS; 2000 Jan; 14(1):51-7. PubMed ID: 10714567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid results of partial ileal bypass in patients with heterozygous, type II-A hyperlipoproteinemia. Program on the Surgical Control of the Hyperlipidemias.
    Campos CT; Matts JP; Fitch LL; Speech JC; Long JM; Buchwald H
    Surgery; 1990 Oct; 108(4):601-10; discussion 610-1. PubMed ID: 2120785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.
    Cahn PE; Gatell JM; Squires K; Percival LD; Piliero PJ; Sanne IA; Shelton S; Lazzarin A; Odeshoo L; Kelleher TD; Thiry A; Giordano MD; Schnittman SM
    J Int Assoc Physicians AIDS Care (Chic); 2004; 3(3):92-8. PubMed ID: 15573713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
    Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
    Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of treatment-induced lipid abnormalities and lipodystrophy.
    Smith D
    J HIV Ther; 2001 May; 6(2):25-7. PubMed ID: 11501199
    [No Abstract]   [Full Text] [Related]  

  • 27. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy.
    Eirís J; Novo-Rodríguez MI; Del Río M; Meseguer P; Del Río MC; Castro-Gago M
    Epilepsy Res; 2000 Aug; 41(1):1-7. PubMed ID: 10924863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipid profile changes by high activity anti-retroviral therapy.
    Duro M; Sarmento-Castro R; Almeida C; Medeiros R; Rebelo I
    Clin Biochem; 2013 Jun; 46(9):740-4. PubMed ID: 23295258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment durability, effectiveness, and safety with atazanavir/ritonavir-based HAART regimen in treatment-naïve HIV-infected patients.
    Tremblay C; Trottier B; Rachlis A; Baril JG; Loutfy M; Lalonde R; Sampalis JS; Boulerice F
    HIV Clin Trials; 2011; 12(3):151-60. PubMed ID: 21684855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia.
    Shahmanesh M; Das S; Stolinski M; Shojaee-Moradie F; Jackson NC; Jefferson W; Cramb R; Nightingale P; Umpleby AM
    J Clin Endocrinol Metab; 2005 Feb; 90(2):755-60. PubMed ID: 15522931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity?
    Badiou S; Merle De Boever C; Dupuy AM; Baillat V; Cristol JP; Reynes J
    Atherosclerosis; 2003 May; 168(1):107-13. PubMed ID: 12732393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy.
    Saumoy M; Sánchez-Quesada JL; Martínez E; Llibre JM; Ribera E; Knobel H; Gatell JM; Clotet B; Curran A; Curto J; Masó M; Ordoñez-Llanos J; Podzamczer D
    Atherosclerosis; 2012 Nov; 225(1):200-7. PubMed ID: 23017355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
    Koppel K; Bratt G; Eriksson M; Sandström E
    Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment.
    Keiser PH; Sension MG; DeJesus E; Rodriguez A; Olliffe JF; Williams VC; Wakeford JH; Snidow JW; Shachoy-Clark AD; Fleming JW; Pakes GE; Hernandez JE;
    BMC Infect Dis; 2005 Jan; 5():2. PubMed ID: 15647105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.
    Riddler SA; Li X; Chu H; Kingsley LA; Dobs A; Evans R; Palella F; Visscher B; Chmiel JS; Sharrett A
    HIV Med; 2007 Jul; 8(5):280-7. PubMed ID: 17561873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen.
    Badiou S; De Boever CM; Dupuy AM; Baillat V; Cristol JP; Reynes J
    AIDS; 2003 Mar; 17(5):772-4. PubMed ID: 12646808
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum lipid profile in highly active antiretroviral therapy-naïve HIV-infected patients in Cameroon: a case-control study.
    Nguemaïm NF; Mbuagbaw J; Nkoa T; Alemnji G; Této G; Fanhi TC; Asonganyi T; Samé-Ekobo A
    HIV Med; 2010 Jul; 11(6):353-9. PubMed ID: 20345886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy.
    Bard JM; Lassalle R; Capeau J; Bach-Ngohou K; Nazih-Sanderson F; Rémy G; Reynes J; Ecobichon JL; Savès M; Raffi F;
    Antivir Ther; 2006; 11(3):361-70. PubMed ID: 16759053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.